{"id":"pazopanib-sorafenib","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1200485","moleculeType":"Small molecule","molecularWeight":"637.04"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pazopanib and sorafenib are both multi-targeted receptor tyrosine kinase inhibitors that suppress vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and RAF kinase signaling. By combining these agents, the regimen aims to achieve broader kinase inhibition and potentially overcome resistance mechanisms in cancer cells. This dual approach targets both tumor vasculature and intrinsic oncogenic pathways.","oneSentence":"This combination of two tyrosine kinase inhibitors blocks multiple receptor pathways (VEGFR, PDGFR, RAF kinase) to inhibit tumor angiogenesis and cell proliferation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:25:47.766Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic renal cell carcinoma"},{"name":"Other solid tumors (under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":554},{"nctId":"NCT02029001","phase":"PHASE2","title":"Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2014-03","conditions":"Malignant Solid Neoplasms","enrollment":900},{"nctId":"NCT04659343","phase":"","title":"TDM for Optimized Outcome in Patients With mRCC.","status":"RECRUITING","sponsor":"Niels Fristrup","startDate":"2020-11-01","conditions":"Kidney Cancer, Renal Cell Carcinoma Metastatic, Drug Toxicity","enrollment":200},{"nctId":"NCT05363072","phase":"","title":"A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-05-02","conditions":"Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney","enrollment":1112},{"nctId":"NCT02776644","phase":"","title":"Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10-15","conditions":"Renal Cell Carcinoma","enrollment":1349},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT01664182","phase":"PHASE2","title":"Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-01","conditions":"Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":41},{"nctId":"NCT01636908","phase":"NA","title":"Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2011-08","conditions":"Cancer, Advanced Solid Tumors","enrollment":43},{"nctId":"NCT02071719","phase":"","title":"Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients","status":"TERMINATED","sponsor":"M. Labots","startDate":"2012-04","conditions":"Renal Cell Cancer","enrollment":6},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT02187302","phase":"PHASE2","title":"CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)","status":"COMPLETED","sponsor":"NewLink Genetics Corporation","startDate":"2014-07","conditions":"Metastatic Renal Cell Carcinoma","enrollment":115},{"nctId":"NCT00610012","phase":"","title":"Tumor Registry of Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2007-12","conditions":"Renal Cell Carcinoma","enrollment":1500},{"nctId":"NCT02638428","phase":"PHASE2","title":"Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2015-12","conditions":"Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML","enrollment":90},{"nctId":"NCT02406521","phase":"PHASE1","title":"Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-04","conditions":"Metastatic Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT01731158","phase":"PHASE2","title":"Sequential Therapy in Metastatic Renal Cell Carinoma","status":"COMPLETED","sponsor":"Central European Society for Anticancer Drug Research","startDate":"2012-10","conditions":"Metastatic Renal Cell Carcinoma","enrollment":22},{"nctId":"NCT02560012","phase":"PHASE2","title":"Personalized Targeted Inhibitors Treatment in Renal Cell Cancer","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-01-04","conditions":"Carcinoma, Renal Cell","enrollment":4},{"nctId":"NCT02086734","phase":"","title":"Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2012-04","conditions":"Metastatic Renal Cancer","enrollment":60},{"nctId":"NCT02122003","phase":"PHASE2","title":"Second Line Sorafenib After Pazopanib in Patients With RCC","status":"TERMINATED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2016-09","conditions":"Metastatic Renal Cell Carcinoma","enrollment":16},{"nctId":"NCT01613846","phase":"PHASE3","title":"Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2012-05","conditions":"Renal Cell Carcinoma","enrollment":544},{"nctId":"NCT01758575","phase":"","title":"Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2012-11","conditions":"Advanced or Metastatic Solid Malignancy","enrollment":8},{"nctId":"NCT01446224","phase":"","title":"Cardiovascular and Torsades de Pointes Monitoring for Pazopanib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Carcinoma, Renal Cell","enrollment":1},{"nctId":"NCT01449825","phase":"","title":"Hepatic Monitoring for Pazopanib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Carcinoma, Renal Cell","enrollment":1},{"nctId":"NCT01381614","phase":"","title":"Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Carcinoma, Renal Cell","enrollment":1},{"nctId":"NCT01381601","phase":"","title":"Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Carcinoma, Renal Cell","enrollment":1},{"nctId":"NCT01700699","phase":"","title":"Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors","status":"UNKNOWN","sponsor":"University of Salerno","startDate":"2012-10","conditions":"Differentiated Thyroid Cancer","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pazopanib+Sorafenib","genericName":"Pazopanib+Sorafenib","companyName":"Technical University of Munich","companyId":"technical-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of two tyrosine kinase inhibitors blocks multiple receptor pathways (VEGFR, PDGFR, RAF kinase) to inhibit tumor angiogenesis and cell proliferation. Used for Advanced or metastatic renal cell carcinoma, Other solid tumors (under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}